445 related articles for article (PubMed ID: 19820283)
1. The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.
Bays HE; Maki KC; Doyle RT; Stein E
Postgrad Med; 2009 Sep; 121(5):145-50. PubMed ID: 19820283
[TBL] [Abstract][Full Text] [Related]
2. Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.
Roth EM; Bays HE; Forker AD; Maki KC; Carter R; Doyle RT; Stein EA
J Cardiovasc Pharmacol; 2009 Sep; 54(3):196-203. PubMed ID: 19597368
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and tolerability of adding prescription omega-3 fatty acids 4 g/d to simvastatin 40 mg/d in hypertriglyceridemic patients: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Stein EA; Bays HE; Maki KC; Doyle RT; Shalwitz RA; Ballantyne CM; Ginsberg HN;
Clin Ther; 2007 Jul; 29(7):1354-67. PubMed ID: 17825687
[TBL] [Abstract][Full Text] [Related]
4. Baseline lipoprotein lipids and low-density lipoprotein cholesterol response to prescription omega-3 acid ethyl ester added to Simvastatin therapy.
Maki KC; Dicklin MR; Davidson MH; Doyle RT; Ballantyne CM;
Am J Cardiol; 2010 May; 105(10):1409-12. PubMed ID: 20451686
[TBL] [Abstract][Full Text] [Related]
5. Long-term up to 24-month efficacy and safety of concomitant prescription omega-3-acid ethyl esters and simvastatin in hypertriglyceridemic patients.
Bays HE; Maki KC; McKenney J; Snipes R; Meadowcroft A; Schroyer R; Doyle RT; Stein E
Curr Med Res Opin; 2010 Apr; 26(4):907-15. PubMed ID: 20156032
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.
Davidson MH; Bays H; Rhyne J; Stein E; Rotenberg K; Doyle R
Clin Ther; 2005 Jun; 27(6):715-27. PubMed ID: 16117978
[TBL] [Abstract][Full Text] [Related]
7. Effects of adding prescription omega-3 acid ethyl esters to simvastatin (20 mg/day) on lipids and lipoprotein particles in men and women with mixed dyslipidemia.
Maki KC; McKenney JM; Reeves MS; Lubin BC; Dicklin MR
Am J Cardiol; 2008 Aug; 102(4):429-33. PubMed ID: 18678300
[TBL] [Abstract][Full Text] [Related]
8. Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.
McKenney JM; Sica D
Pharmacotherapy; 2007 May; 27(5):715-28. PubMed ID: 17461707
[TBL] [Abstract][Full Text] [Related]
9. Randomized study of the safety and efficacy of fish oil (omega-3 fatty acid) supplementation with dietary and exercise counseling for the treatment of antiretroviral therapy-associated hypertriglyceridemia.
Wohl DA; Tien HC; Busby M; Cunningham C; Macintosh B; Napravnik S; Danan E; Donovan K; Hossenipour M; Simpson RJ
Clin Infect Dis; 2005 Nov; 41(10):1498-504. PubMed ID: 16231263
[TBL] [Abstract][Full Text] [Related]
10. Omega-3 fatty acid concentrates in the treatment of moderate hypertriglyceridemia.
Skulas-Ray AC; West SG; Davidson MH; Kris-Etherton PM
Expert Opin Pharmacother; 2008 May; 9(7):1237-48. PubMed ID: 18422480
[TBL] [Abstract][Full Text] [Related]
11. Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.
Rosenson RS; Wolff DA; Huskin AL; Helenowski IB; Rademaker AW
Diabetes Care; 2007 Aug; 30(8):1945-51. PubMed ID: 17483155
[TBL] [Abstract][Full Text] [Related]
12. A randomized placebo-controlled double-blind trial of lipid-lowering strategies in patients with renal insufficiency: diet modification with or without fenofibrate.
Levin A; Duncan L; Djurdjev O; Shapiro RJ; Frohlich J; Belanger A; Dumas R; Ross S
Clin Nephrol; 2000 Feb; 53(2):140-6. PubMed ID: 10711416
[TBL] [Abstract][Full Text] [Related]
13. Omega-3 free fatty acids for the treatment of severe hypertriglyceridemia: the EpanoVa fOr Lowering Very high triglyceridEs (EVOLVE) trial.
Kastelein JJ; Maki KC; Susekov A; Ezhov M; Nordestgaard BG; Machielse BN; Kling D; Davidson MH
J Clin Lipidol; 2014; 8(1):94-106. PubMed ID: 24528690
[TBL] [Abstract][Full Text] [Related]
14. Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.
Rosenson RS
Am Heart J; 2008 Mar; 155(3):499.e9-16. PubMed ID: 18294485
[TBL] [Abstract][Full Text] [Related]
15. One-year ad libitum consumption of diacylglycerol oil as part of a regular diet results in modest weight loss in comparison with consumption of a triacylglycerol control oil in overweight Japanese subjects.
Kawashima H; Takase H; Yasunaga K; Wakaki Y; Katsuragi Y; Mori K; Yamaguchi T; Hase T; Matsuo N; Yasukawa T; Tokimitsu I; Koyama W
J Am Diet Assoc; 2008 Jan; 108(1):57-66. PubMed ID: 18155990
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).
Grundy SM; Vega GL; Yuan Z; Battisti WP; Brady WE; Palmisano J
Am J Cardiol; 2005 Feb; 95(4):462-8. PubMed ID: 15695129
[TBL] [Abstract][Full Text] [Related]
17. Prescription omega-3 acid ethyl esters plus simvastatin 20 and 80 mg: effects in mixed dyslipidemia.
Maki KC; Lubin BC; Reeves MS; Dicklin MR; Harris WS
J Clin Lipidol; 2009 Feb; 3(1):33-8. PubMed ID: 21291786
[TBL] [Abstract][Full Text] [Related]
18. The effect of n - 3 PUFA/gamma-cyclodextrin complex on serum lipids in healthy volunteers--a randomized, placebo-controlled, double-blind trial.
Kobayashi K; Hamazaki K; Fujioka S; Terao K; Yamamoto J; Kobayashi S
Asia Pac J Clin Nutr; 2007; 16(3):429-34. PubMed ID: 17704023
[TBL] [Abstract][Full Text] [Related]
19. [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].
Zeman M; Zák A; Vecka M; Tvrzická E; Písaríková A; Stanková B
Cas Lek Cesk; 2005; 144(11):737-41. PubMed ID: 16335699
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.
McKenney JM; Farnier M; Lo KW; Bays HE; Perevozkaya I; Carlson G; Davies MJ; Mitchel YB; Gumbiner B
J Am Coll Cardiol; 2006 Apr; 47(8):1584-7. PubMed ID: 16630994
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
